Roche IL-12 kidney cancer trials will continue after meeting with FDA, Genetics Institute.
Executive Summary
ROCHE INTERFERON-12 TRIALS FOR KIDNEY CANCER WILL CONTINUE following meetings with FDA's Center for Biologics Evaluation & Research, Genetics Institute and clinical researchers on June 15. Roche has been conducting Phase I trials at several U.S. sites of its subcutaneous-administration, recombinant human interferon-12. Roche's IL-12 is reportedly administered once a week. The National Kidney Cancer Association sent a letter to FDA Commissioner Kessler asking that the Roche trials be continued with close monitoring of patients to watch for emergence of side effects.